Is Ginkgo Bioworks a Warren Buffett Stock?
Buffett didn't get rich by buying biotechs, and his traditional value investing perspective is difficult to square with the industry's frequently unprofitable businesses.
But could a company with a highly repeatable and difficult-to-imitate business like Ginkgo Bioworks (NYSE: DNA) buck the trend and become a Buffett favorite? In my view, it's more likely than it may sound.
Image source: Getty Images.
Source Fool.com
